Review Of BMS's CAR-T Therapy Liso-Cel Gets Under Way At EMA
There Are Six Additions To The List Of Products Seeking EU Approval
Executive Summary
Bristol Myers Squibb's lisocabtagene maraleucel, UCB's bimekizumab and Rhythm Pharmaceuticals' setmelanotide are among the six latest additions to the list of products under review at the European Medicines Agency.
You may also be interested in...
EU Accelerated Assessment Tracker
Two products that were under fast-track review at the European Medicines Agency have reverted to standard review timelines – Eiger's lonafarnib and GSK's dostarlimab. The Pink Sheet tracker logs these and other developments relating to the agency's accelerated assessment mechanism.
Eiger's Lonafarnib Loses EU Fast-Track Review Status
Eiger attributes the change in status of the EU marketing authorization application for lonafarnib to the need for an inspection and the ongoing coronavirus pandemic.
Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First
As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta.